{
  "nodes": [
    {
      "node_id": "A",
      "step_index": 0,
      "timestamp": "2015-01-01T00:00:00Z",
      "commentary": "Initial presentation with right flank pain and bloody stools. Diagnosis of metastatic KRAS wild-type colorectal cancer.",
      "data": {
        "demographics": {
          "age": 48,
          "sex": "unknown"
        },
        "conditions": [
          {
            "condition": "Metastatic colorectal cancer",
            "evidence": "Liver, lung, and adrenal metastases on CT",
            "site": ["liver", "lung", "adrenal"],
            "diagnosis_method": "core needle biopsy of liver nodule"
          },
          {
            "condition": "Anemia",
            "evidence": "Hemoglobin 7.1 g/dL"
          }
        ],
        "labs": [
          {
            "test": "Hemoglobin",
            "value": 7.1,
            "unit": "g/dL"
          }
        ],
        "observations": [
          {
            "finding": "Bloody stools",
            "duration": "1 week"
          },
          {
            "finding": "Right flank pain"
          }
        ],
        "treatments": [],
        "metadata": {
          "journal_id": "JCO_Precision_Oncology_2017",
          "doi": "10.1200/PO.16.00055",
          "corpus_timestamp": "2017-06-27T00:00:00Z",
          "schema_version": "1.0"
        }
      }
    },
    {
      "node_id": "B",
      "step_index": 1,
      "timestamp": "2015-01-15T00:00:00Z",
      "commentary": "Initiation of first-line palliative chemotherapy with capecitabine and oxaliplatin. Bevacizumab not given due to rectal bleeding and DVT history.",
      "data": {
        "treatments": [
          {
            "agent": "Capecitabine",
            "indication": "mCRC",
            "route": "oral",
            "regimen": "every 3 weeks"
          },
          {
            "agent": "Oxaliplatin",
            "indication": "mCRC",
            "route": "IV",
            "regimen": "every 3 weeks"
          }
        ],
        "conditions": [
          {
            "condition": "Metastatic colorectal cancer",
            "status": "stable disease"
          }
        ],
        "metadata": {
          "journal_id": "JCO_Precision_Oncology_2017",
          "doi": "10.1200/PO.16.00055",
          "corpus_timestamp": "2017-06-27T00:00:00Z",
          "schema_version": "1.0"
        }
      }
    },
    {
      "node_id": "C",
      "step_index": 2,
      "timestamp": "2015-07-15T00:00:00Z",
      "commentary": "Disease progression after 6 months. Liver and lung lesions increased in size; new adrenal metastasis.",
      "data": {
        "conditions": [
          {
            "condition": "Metastatic colorectal cancer",
            "status": "progressive disease",
            "sites": ["liver", "lung", "adrenal"]
          }
        ],
        "observations": [
          {
            "finding": "New adrenal gland metastasis"
          }
        ],
        "metadata": {
          "journal_id": "JCO_Precision_Oncology_2017",
          "doi": "10.1200/PO.16.00055",
          "corpus_timestamp": "2017-06-27T00:00:00Z",
          "schema_version": "1.0"
        }
      }
    },
    {
      "node_id": "D",
      "step_index": 3,
      "timestamp": "2015-10-01T00:00:00Z",
      "commentary": "Subsequent lines of therapy: capecitabine + irinotecan ± cetuximab, then regorafenib (poorly tolerated). No response.",
      "data": {
        "treatments": [
          {
            "agent": "Capecitabine + irinotecan ± cetuximab",
            "indication": "Progressive mCRC",
            "status": "failed"
          },
          {
            "agent": "Regorafenib",
            "indication": "Refractory mCRC",
            "status": "discontinued",
            "reason": "poorly tolerated"
          }
        ],
        "conditions": [
          {
            "condition": "Metastatic colorectal cancer",
            "status": "progressive disease"
          }
        ],
        "metadata": {
          "journal_id": "JCO_Precision_Oncology_2017",
          "doi": "10.1200/PO.16.00055",
          "corpus_timestamp": "2017-06-27T00:00:00Z",
          "schema_version": "1.0"
        }
      }
    },
    {
      "node_id": "E",
      "step_index": 4,
      "timestamp": "2016-01-01T00:00:00Z",
      "commentary": "Next-gen sequencing revealed HER2 amplification. Tumor board deemed it actionable. Started trastuzumab (unsuccessful).",
      "data": {
        "labs": [
          {
            "test": "Next-generation sequencing",
            "findings": [
              "HER2 (ERBB2) amplification",
              "APC R232*",
              "TP53 splice site 97_1G>A"
            ]
          }
        ],
        "treatments": [
          {
            "agent": "Trastuzumab",
            "indication": "HER2+ mCRC",
            "status": "failed"
          }
        ],
        "metadata": {
          "journal_id": "JCO_Precision_Oncology_2017",
          "doi": "10.1200/PO.16.00055",
          "corpus_timestamp": "2017-06-27T00:00:00Z",
          "schema_version": "1.0"
        }
      }
    },
    {
      "node_id": "F",
      "step_index": 5,
      "timestamp": "2016-04-01T00:00:00Z",
      "commentary": "Initiated ado-trastuzumab emtansine (T-DM1). Durable partial response over 15 months; lesion shrank from 5.3 cm to 2.1 cm. Patient eventually progressed and died under hospice care.",
      "data": {
        "treatments": [
          {
            "agent": "Ado-trastuzumab emtansine (T-DM1)",
            "route": "IV",
            "regimen": "every 21 days",
            "duration": "15 months",
            "response": "partial response"
          }
        ],
        "conditions": [
          {
            "condition": "Metastatic colorectal cancer",
            "status": "responsive (partial)",
            "evidence": "Target lesion reduction from 5.3 to 2.1 cm; two lesions fully resolved"
          }
        ],
        "metadata": {
          "journal_id": "JCO_Precision_Oncology_2017",
          "doi": "10.1200/PO.16.00055",
          "corpus_timestamp": "2017-06-27T00:00:00Z",
          "schema_version": "1.0"
        }
      }
    }
  ],
  "edges": [
    {
      "edge_id": "A_to_B",
      "from_node": "A",
      "to_node": "B",
      "step_index": 1,
      "event_type": "Intervention",
      "commentary": "Initiation of first-line chemotherapy with capecitabine and oxaliplatin.",
      "changes": [
        {
          "field": "treatments",
          "change_type": "add",
          "value": ["Capecitabine", "Oxaliplatin"]
        }
      ]
    },
    {
      "edge_id": "B_to_C",
      "from_node": "B",
      "to_node": "C",
      "step_index": 2,
      "event_type": "Observation",
      "commentary": "Disease progression after 6 months of first-line therapy.",
      "changes": [
        {
          "field": "conditions",
          "change_type": "update",
          "from": "stable disease",
          "to": "progressive disease"
        }
      ]
    },
    {
      "edge_id": "C_to_D",
      "from_node": "C",
      "to_node": "D",
      "step_index": 3,
      "event_type": "Intervention",
      "commentary": "Second and third-line therapies attempted without success.",
      "changes": [
        {
          "field": "treatments",
          "change_type": "add",
          "value": ["Capecitabine + irinotecan ± cetuximab", "Regorafenib"]
        }
      ]
    },
    {
      "edge_id": "D_to_E",
      "from_node": "D",
      "to_node": "E",
      "step_index": 4,
      "event_type": "Observation",
      "commentary": "Molecular tumor board identifies HER2 amplification. Trastuzumab initiated but ineffective.",
      "changes": [
        {
          "field": "labs",
          "change_type": "add",
          "value": ["HER2 amplification via NGS"]
        },
        {
          "field": "treatments",
          "change_type": "add",
          "value": ["Trastuzumab"]
        }
      ]
    },
    {
      "edge_id": "E_to_F",
      "from_node": "E",
      "to_node": "F",
      "step_index": 5,
      "event_type": "Intervention",
      "commentary": "T-DM1 initiated with partial durable response. Eventually patient dies.",
      "changes": [
        {
          "field": "treatments",
          "change_type": "add",
          "value": ["Ado-trastuzumab emtansine (T-DM1)"]
        },
        {
          "field": "conditions",
          "change_type": "update",
          "from": "progressive disease",
          "to": "responsive (partial)"
        }
      ]
    }
  ]
}
